Colgate exec exercises options, sells 20,989 shares

Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share.

Rhea-AI Filing Summary

Colgate-Palmolive Chief Growth Officer Hazlin John exercised stock options for 20,989 shares of common stock at $76.41 per share on February 10, 2026, then sold 20,989 shares at a weighted average price of $94.2499 per share. A portion of the sale proceeds was delivered to the company to pay the option exercise price and related tax withholding. After these transactions, John directly owned 17,645 shares and indirectly held 5,452 shares through the issuer's 401(k) plan trustee.

Insider Trade Summary

Exercise and Sale: 20,989 shares ($374K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Hazlin John

Role Chief Growth Officer

Sold 20,989 shs ($1.98M)

Approx. gross sale proceeds $1.98M

Approx. exercise cost $1.60M

Approx. pre-tax spread $374K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	20,989	$0.00	$0.00
Exercise	Common Stock	20,989	$76.41	$1.60M
Sale	Common Stock	20,989	$94.2499	$1.98M
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 17,645 shares (Direct); Common Stock — 5,452 shares (Indirect, By Issuer's 401(k) Plan Trustee)

Footnotes (4)

1. F1. Exercise of stock options awarded under the issuer's incentive compensation plan.
2. F2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.
3. F3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.19 to $94.30 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Hazlin John report at Colgate-Palmolive (CL)?

Hazlin John reported exercising stock options for 20,989 Colgate-Palmolive shares and selling 20,989 common shares on February 10, 2026. The sale followed the option exercise and was executed at a weighted average price of $94.2499 per share.

How many Colgate-Palmolive (CL) shares did Hazlin John sell and at what price?

Hazlin John sold 20,989 Colgate-Palmolive common shares at a weighted average price of $94.2499. The filing notes the shares were sold in multiple trades between $94.19 and $94.30, with detailed breakdowns available on request.

What stock options did Hazlin John exercise in this Colgate-Palmolive (CL) Form 4?

He exercised a stock option for 20,989 Colgate-Palmolive shares at an exercise price of $76.41 per share. These options were granted under the company’s incentive compensation plan and became exercisable in one-third increments after the September 10, 2020 grant date.

How many Colgate-Palmolive (CL) shares does Hazlin John own after the reported transactions?

Following the option exercise and share sale, Hazlin John directly owned 17,645 Colgate-Palmolive common shares. He also had an additional 5,452 shares held indirectly through the issuer’s 401(k) plan trustee, according to the Form 4.

Were the sale proceeds from Hazlin John’s Colgate-Palmolive (CL) trade used to cover costs?

Yes. The filing states that a portion of the sale proceeds was delivered to Colgate-Palmolive to pay the exercise price of the options and the related tax withholding, as part of the company’s incentive compensation plan.

What happened to Hazlin John’s Colgate-Palmolive (CL) stock option position after the transaction?

After exercising the option covering 20,989 shares, Hazlin John no longer held this stock option position. The number of derivative securities beneficially owned following the transaction is shown as zero in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hazlin John

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Growth Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		M(1)		20,989	A	$76.41	38,634	D
Common Stock	02/10/2026		S(2)		20,989	D	$94.2499(3)	17,645	D
Common Stock								5,452	I	By Issuer's 401(k) Plan Trustee

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.41	02/10/2026		M(1)			20,989	(4)	09/10/2028	Common Stock	20,989	$0.0000	0.0000	D

Explanation of Responses:

1. Exercise of stock options awarded under the issuer's incentive compensation plan.

2. Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding.

3. Weighted average price, as these shares were sold in multiple transactions at prices ranging from $94.19 to $94.30 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.